151 related articles for article (PubMed ID: 32350747)
1. Evaluation of goserelin effectiveness based on assessment of inflammatory cytokines and symptoms in uterine leiomyoma.
Mohammed NH; Al-Taie A; Albasry Z
Int J Clin Pharm; 2020 Jun; 42(3):931-937. PubMed ID: 32350747
[TBL] [Abstract][Full Text] [Related]
2. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
3. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.
Perry CM; Brogden RN
Drugs; 1996 Feb; 51(2):319-46. PubMed ID: 8808170
[TBL] [Abstract][Full Text] [Related]
4. The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group.
Gerris J; Degueldre M; Peters AA; Romao F; Stjernquist M; al-Taher H
Horm Res; 1996; 45(6):279-84. PubMed ID: 8793522
[TBL] [Abstract][Full Text] [Related]
5. Genic expression of the uterine leiomyoma in reproductive-aged women after treatment with goserelin.
Borsari R; Bozzini N; Junqueira CR; Soares JM; Hilário SG; Baracat EC
Fertil Steril; 2010 Aug; 94(3):1072-7. PubMed ID: 19481745
[TBL] [Abstract][Full Text] [Related]
6. Cellular leiomyoma mimicking endometrial stromal neoplasm in association with GnRH agonist goserelin.
McCluggage WG; Bharucha H
Histopathology; 1999 Feb; 34(2):184-6. PubMed ID: 10064405
[No Abstract] [Full Text] [Related]
7. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids.
Morris EP; Rymer J; Robinson J; Fogelman I
Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410
[TBL] [Abstract][Full Text] [Related]
8. Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure.
Bozzini N; Rodrigues CJ; Petti DA; Bevilacqua RG; Gonçalves SP; Pinotti JA
Acta Obstet Gynecol Scand; 2003 Apr; 82(4):330-4. PubMed ID: 12716317
[TBL] [Abstract][Full Text] [Related]
9. Treatment with the gonadotrophin releasing hormone-agonist goserelin before hysterectomy for uterine fibroids.
Lumsden MA; West CP; Thomas E; Coutts J; Hillier H; Thomas N; Baird DT
Br J Obstet Gynaecol; 1994 May; 101(5):438-42. PubMed ID: 8018618
[TBL] [Abstract][Full Text] [Related]
10. [Clinical uses of goserelin in gynecologic diseases and its safety].
Tan SJ; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 1998 Jan; 33(1):58-60. PubMed ID: 10682460
[No Abstract] [Full Text] [Related]
11. Uterine myoma after cessation of gonadotropin-releasing hormone agonist: ultrasound and histopathologic findings.
Wang PH; Yang AH; Yuan CC; Lee WL; Chao HT
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Nov; 61(11):625-9. PubMed ID: 9872018
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of goserelin (Zoladex) in the treatment of uterine myomas in infertile patients.
Kopitović V; Bujas M; Fistes Topalski N; Pjević M; Ilić D; Kapamadzija A; Bujas I
Med Pregl; 2001; 54(7-8):339-46. PubMed ID: 11905182
[TBL] [Abstract][Full Text] [Related]
13. [Hysteroresection of submucous myomas after treatment with zoladex].
Tiufekchieva E; Nikolov A
Akush Ginekol (Sofiia); 2006; 45(1):19-24. PubMed ID: 16637313
[TBL] [Abstract][Full Text] [Related]
14. Treatment of submucous fibroids, and outcome of assisted conception.
Narayan R; Rajat ; Goswamy K
J Am Assoc Gynecol Laparosc; 1994 Aug; 1(4 Pt 1):307-11. PubMed ID: 9138869
[TBL] [Abstract][Full Text] [Related]
15. GnRH agonists: an alternative to surgery?
Maheux R
Hum Reprod; 1996 Nov; 11 Suppl 3():43-50. PubMed ID: 9147101
[No Abstract] [Full Text] [Related]
16. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
17. Morphological changes in uterine leiomyomas treated by GnRH agonist goserelin.
Crow J; Gardner RL; McSweeney G; Shaw RW
Int J Gynecol Pathol; 1995 Jul; 14(3):235-42. PubMed ID: 8600075
[TBL] [Abstract][Full Text] [Related]
18. The influence of luteinizing hormone-releasing hormone analog on serum leptin and body composition in women with solitary uterine myoma.
Nowicki M; Adamkiewicz G; Bryc W; Kokot F
Am J Obstet Gynecol; 2002 Mar; 186(3):340-4. PubMed ID: 11904588
[TBL] [Abstract][Full Text] [Related]
19. [Effect of GnRH analogues pre-treatment on myomectomy outcomes in reproductive age women].
Hudecek R; Ivanová Z; Smerdová M; Pánková S; Krajcovicová R
Ceska Gynekol; 2012 Apr; 77(2):109-17. PubMed ID: 22702067
[TBL] [Abstract][Full Text] [Related]
20. Relationship between gonadotropin-releasing hormone agonist and myoma cellular activity: preliminary findings on positron emission tomography.
Lee WL; Liu RS; Yuan CC; Chao HT; Wang PH
Fertil Steril; 2001 Mar; 75(3):638-9. PubMed ID: 11239559
[No Abstract] [Full Text] [Related]
[Next] [New Search]
